Cargando…
Modulating FKBP5/FKBP51 and autophagy lowers HTT (huntingtin) levels
Current disease-modifying therapies for Huntington disease (HD) focus on lowering mutant HTT (huntingtin; mHTT) levels, and the immunosuppressant drug rapamycin is an intriguing therapeutic for aging and neurological disorders. Rapamycin interacts with FKBP1A/FKBP12 and FKBP5/FKBP51, inhibiting the...
Autores principales: | Bailus, Barbara J., Scheeler, Stephen M., Simons, Jesse, Sanchez, Maria A., Tshilenge, Kizito-Tshitoko, Creus-Muncunill, Jordi, Naphade, Swati, Lopez-Ramirez, Alejandro, Zhang, Ningzhe, Lakshika Madushani, Kuruwitage, Moroz, Stanislav, Loureiro, Ashley, Schreiber, Katherine H., Hausch, Felix, Kennedy, Brian K., Ehrlich, Michelle E., Ellerby, Lisa M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726715/ https://www.ncbi.nlm.nih.gov/pubmed/34024231 http://dx.doi.org/10.1080/15548627.2021.1904489 |
Ejemplares similares
-
FOXO3 targets are reprogrammed as Huntington's disease neural cells and striatal neurons face senescence with p16(INK4a) increase
por: Voisin, Jessica, et al.
Publicado: (2020) -
The Many Faces of FKBP51
por: Hähle, Andreas, et al.
Publicado: (2019) -
FKBP51 and FKBP12.6—Novel and tight interactors of Glomulin
por: Hähle, Andreas, et al.
Publicado: (2019) -
Altered Expression of Matrix Metalloproteinases and Their Endogenous Inhibitors in a Human Isogenic Stem Cell Model of Huntington's Disease
por: Naphade, Swati, et al.
Publicado: (2018) -
Biological Actions of the Hsp90-binding Immunophilins FKBP51 and FKBP52
por: Zgajnar, Nadia R., et al.
Publicado: (2019)